Emageon evaluating strategic optionsperhaps a sale?

Emageon, a provider of medical IT systems, has reported that it plans to evaluate its available strategic options, which could indicate a potential sale of the company.

To that end, the company has chosen Jefferies and Company, an investment bank and institutional securities firm, to act in a lead advisory capacity.

SunTrust Robinson Humphrey, which provides capital raising, strategic advisory, risk management and investment proposals, has been appointed to co-advise, according to the Birmingham, Ala.-based company.

Emageon lost $4.6 million in the first quarter of 2008 as revenue dropped 30 percent to $19.3 million, and also recently settled a proxy contest with New York City-based Oliver Press Partners, a major shareholder. The settlement has caused a shake-up within Emageon’s board of directors.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.